Your browser is no longer supported. Please, upgrade your browser.
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E39.94 EPS (ttm)2.83 Insider Own0.10% Shs Outstand1.77B Perf Week-1.99%
Market Cap201.21B Forward P/E8.13 EPS next Y13.92 Insider Trans-16.38% Shs Float1.76B Perf Month-2.36%
Income5.08B PEG8.88 EPS next Q3.08 Inst Own68.90% Short Float0.84% Perf Quarter9.38%
Sales50.20B P/S4.01 EPS this Y-48.50% Inst Trans-0.86% Short Ratio2.19 Perf Half Y8.10%
Book/sh7.75 P/B14.60 EPS next Y10.77% ROA3.40% Target Price123.82 Perf Year17.55%
Cash/sh5.50 P/C20.58 EPS next 5Y4.50% ROE35.80% 52W Range79.11 - 118.28 Perf YTD5.57%
Dividend5.20 P/FCF21.15 EPS past 5Y-2.80% ROI12.70% 52W High-4.36% Beta0.80
Dividend %4.60% Quick Ratio0.70 Sales past 5Y14.90% Gross Margin64.90% 52W Low42.99% ATR1.80
Employees48000 Current Ratio0.80 Sales Q/Q50.90% Oper. Margin23.60% RSI (14)46.06 Volatility1.24% 1.51%
OptionableYes Debt/Eq6.24 EPS Q/Q6.50% Profit Margin10.10% Rel Volume1.09 Prev Close114.90
ShortableYes LT Debt/Eq5.41 EarningsApr 30 BMO Payout170.30% Avg Volume6.74M Price113.12
Recom2.00 SMA20-0.98% SMA500.14% SMA2009.67% Volume7,366,099 Change-1.55%
Apr-07-21Resumed RBC Capital Mkts Outperform $135
Nov-10-20Resumed Bernstein Outperform $120
Sep-29-20Initiated Berenberg Hold $98
Jun-23-20Upgrade Atlantic Equities Neutral → Overweight $115
Jun-09-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Upgrade Argus Hold → Buy $115
May-18-20Resumed BofA/Merrill Neutral $95
May-12-20Upgrade JP Morgan Neutral → Overweight $105
May-11-20Resumed Morgan Stanley Overweight $95
Apr-20-20Upgrade RBC Capital Mkts Sector Perform → Outperform $79 → $93
Mar-23-20Downgrade Societe Generale Buy → Hold
Feb-27-20Initiated Barclays Equal Weight $97
Feb-06-20Initiated Mizuho Buy
Jan-07-20Initiated RBC Capital Mkts Sector Perform $86
Dec-26-19Reiterated Cowen Outperform $90 → $98
Sep-26-19Upgrade Citigroup Neutral → Buy $87 → $90
Aug-20-19Upgrade Piper Jaffray Neutral → Overweight $80
Jun-27-19Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19Upgrade SVB Leerink Mkt Perform → Outperform $88
May-28-19Initiated Goldman Neutral
Jun-18-21 12:33PM  
06:49AM  
Jun-17-21 06:29PM  
11:00AM  
10:54AM  
06:00AM  
Jun-16-21 11:45AM  
10:33AM  
09:57AM  
Jun-14-21 06:38PM  
05:45PM  
01:41PM  
07:32AM  
Jun-13-21 05:55AM  
05:28AM  
Jun-12-21 07:02AM  
Jun-11-21 10:11AM  
05:55AM  
01:03AM  
Jun-10-21 06:45AM  
Jun-09-21 11:15AM  
08:30AM  
Jun-08-21 08:45AM  
01:15AM  
Jun-07-21 05:45PM  
02:07PM  
11:30AM  
07:01AM  
Jun-04-21 09:00AM  
Jun-03-21 09:21AM  
Jun-02-21 02:47PM  
02:42PM  
10:02AM  
08:30AM  
08:00AM  
07:30AM  
07:24AM  
07:00AM  
01:44AM  
May-31-21 11:45AM  
May-30-21 05:55AM  
May-29-21 06:42AM  
May-27-21 10:12AM  
06:06AM  
May-26-21 11:34AM  
10:00AM  
08:15AM  
08:00AM  
06:25AM  
May-25-21 08:00AM  
08:00AM  
07:12AM  
06:08AM  
May-24-21 10:48AM  
09:40AM  
09:15AM  
08:45AM  
08:16AM  
May-23-21 05:52AM  
May-22-21 07:11AM  
06:17AM  
May-21-21 04:52PM  
10:26AM  
06:43AM  
May-20-21 08:00AM  
07:00AM  
May-19-21 08:00AM  
May-18-21 05:47PM  
03:40PM  
11:30AM  
11:17AM  
09:48AM  
09:28AM  
09:00AM  
May-16-21 06:01AM  
May-14-21 11:45AM  
08:28AM  
06:20AM  
May-13-21 06:38AM  
May-12-21 08:00AM  
06:43AM  
05:52AM  
May-11-21 06:38PM  
04:46PM  
03:12PM  
11:33AM  
07:53AM  
May-10-21 04:46PM  
04:24PM  
10:27AM  
08:30AM  
04:00AM  
May-09-21 06:01AM  
May-08-21 06:25AM  
06:04AM  
May-07-21 01:13PM  
10:47AM  
05:01AM  
May-05-21 04:40PM  
11:30AM  
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SALEKI-GERHARDT AZITAEVP, OperationsMay 24Option Exercise34.9386,9203,036,230203,204May 26 05:20 PM
SALEKI-GERHARDT AZITAEVP, OperationsMay 24Sale116.2986,92010,108,033116,284May 26 05:20 PM
Strom Carrie CSVP & Pres Global Allerg AesthMay 03Option Exercise41.394,184173,17663,409May 05 04:23 PM
Strom Carrie CSVP & Pres Global Allerg AesthMay 03Sale112.404,184470,28259,225May 05 04:23 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 02Option Exercise54.86170,1139,332,399546,710Mar 02 08:27 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerMar 01Sale108.5919,5142,119,0410Mar 02 08:31 PM
Sorg Elaine K.SVP, US Commercial OperationsMar 01Sale108.618,440916,64217,595Mar 02 08:30 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 01Sale108.61170,11318,476,204376,597Mar 02 08:27 PM
Stewart Jeffrey RyanSVP, US Commercial OperationsMar 01Sale108.5913,7731,495,57650,969Mar 02 08:26 PM
Sorg Elaine K.SVP, US Commercial OperationsFeb 22Option Exercise89.7820,1951,813,05252,946Feb 24 06:28 PM
Sorg Elaine K.SVP, US Commercial OperationsFeb 22Sale104.7220,1952,114,73232,751Feb 24 06:28 PM
Stewart Jeffrey RyanEVP, Commercial OperationsDec 29Option Exercise51.4225,2901,300,41276,259Dec 31 01:15 PM
Stewart Jeffrey RyanEVP, Commercial OperationsDec 29Sale105.0025,2902,655,45050,969Dec 31 01:15 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerNov 27Option Exercise51.4251,9902,673,32651,990Dec 01 05:22 PM
RICHMOND TIMOTHY J.EVP, Chief HR OfficerNov 27Sale105.0051,9905,458,9500Dec 01 05:22 PM
Gosebruch Henry OEVP, Chief Strategy OfficerNov 20Sale99.3840,0003,975,04620,006Nov 24 05:34 PM
ALBAN CARLOSVice ChairmanNov 16Option Exercise35.88115,8304,155,980230,729Nov 18 05:04 PM
ALBAN CARLOSVice ChairmanNov 16Sale100.00115,83011,583,000114,899Nov 18 05:04 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 12Option Exercise57.12194,15411,089,858512,796Nov 12 05:54 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 12Sale97.10194,15418,851,790318,642Nov 12 05:54 PM
SALEKI-GERHARDT AZITAEVP, OperationsNov 10Sale98.0017,4261,707,74896,441Nov 12 05:56 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 09Sale95.7437,4503,585,463318,642Nov 12 05:54 PM
SALEKI-GERHARDT AZITAEVP, OperationsNov 04Sale93.614,800449,328109,067Nov 06 04:29 PM
SEVERINO MICHAELVice ChairmanNov 04Sale93.6190,6798,488,46167,281Nov 06 04:29 PM
ALBAN CARLOSVice ChairmanJul 07Sale100.0053,3255,332,555114,899Jul 08 09:19 PM